<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00677235</url>
  </required_header>
  <id_info>
    <org_study_id>BPV-07-002</org_study_id>
    <nct_id>NCT00677235</nct_id>
  </id_info>
  <brief_title>Post-Approval Study for the FLAIR Endovascular Stent Graft</brief_title>
  <acronym>RENOVA</acronym>
  <official_title>A Prospective, Randomized, Concurrently-Controlled Post-Approval Study of the FLAIR Endovascular Stent Graft</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>C. R. Bard</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>C. R. Bard</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to confirm the long-term safety and effectiveness of the FLAIR
      Endovascular Stent Graft for treatment of stenoses at the venous anastomosis of ePTFE or
      other synthetic arteriovenous (AV) access grafts.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of the study is to compare efficacy data on subjects randomized to treatment with
      percutaneous transluminal angioplasty (PTA) and the FLAIR™ Endovascular Stent Graft versus
      subjects randomized to treatment with PTA only.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ACPP Was Defined as the Interval Following the Index Procedure Until the Next Access Thrombosis or Reintervention.</measure>
    <time_frame>12 months</time_frame>
    <description>To demonstrate that the post intervention Access Circuit Primary Patency (ACPP) of FLAIR™ is superior to that of PTA at 12 months post study procedure.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Index of Patency Function (IPF) [the Average Number of Months Between Interventions] of FLAIR™ is Not Inferior to That of PTA at 12 Months Post Study Procedure.</measure>
    <time_frame>12 months</time_frame>
    <description>The IPF is summarized was defined as the time from the index study procedure to complete graft abandonment divided by the number of visits for a reintervention performed on the arteriovenous (AV) access circuit in order to maintain vascular access for hemodialysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Number of Participants With Device and/or Procedure Related Adverse Events at 12 Months Post Study Procedure.</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To Assess the Number of Re-interventions to the Access Circuit Until Graft Abandonment or Through 12 Months Post-index Procedure</measure>
    <time_frame>Patient Follow-Up</time_frame>
    <description>The estimated number of re-interventions to the access circuit until graft abandonment or through 12 months post-index procedure was a secondary endpoint without hypothesis testing and is therefore summarized descriptively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-Intervention Assisted Primary Patency at 12 Months</measure>
    <time_frame>12 months</time_frame>
    <description>Postintervention assisted primary patency (PAPP) was defined as the interval after the index/study procedure until access thrombosis or a surgical intervention that excluded the treated lesion from the access circuit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-intervention Secondary Patency (PSP) at 12 Months</measure>
    <time_frame>12 months</time_frame>
    <description>Postintervention secondary patency [PSP; referred to as Access Circuit Cumulative Patency (ACCP) in the pivotal trial] was the interval following the treatment procedure until the access circuit was surgically declotted, revised, or abandoned because of inability to treat the original stenosis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural Success</measure>
    <time_frame>Patient Follow-Up</time_frame>
    <description>Procedural success was a secondary endpoint without hypothesis testing and is therefore summarized descriptively. Procedural success is defined as anatomic success and at least one indicator of hemodynamic or clinical success.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of Proportion of Serious Adverse Events Classified as Device and/or Procedure-Related Through 30 Days Post-Procedure</measure>
    <time_frame>Patient Follow-Up</time_frame>
    <description>The incidence of device-related and procedure-related serious adverse events (SAEs) from the index procedure through 30 days post procedure is summarized. The purpose of this analysis was to assess the effectiveness of the Bard Peripheral Vascular (BPV) clinician training program.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Demonstrate Non-inferiority of FLAIR Safety in Terms of Serious Adverse Events at 12 Months</measure>
    <time_frame>12 months</time_frame>
    <description>Serious Adverse Events at 12 months are reported for all 270 subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Access Circuit Primary Patency (ACCP) at 24 Months Procedure Until the Next Access Thrombosis or Reintervention.</measure>
    <time_frame>24 months</time_frame>
    <description>Access Circuit Primary Patency (ACPP) was defined as the interval following the index procedure until the next access thrombosis or reintervention at 24 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Estimate Safety at 24 Months.</measure>
    <time_frame>24 months</time_frame>
    <description>To estimate the percentage of participants without safety issues through 24 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-Intervention Assisted Primary Patency at 24 Months</measure>
    <time_frame>24 month follow up</time_frame>
    <description>Postintervention assisted primary patency (PAPP) was defined as the interval after the index/study procedure until access thrombosis or a surgical intervention that excluded the treated lesion from the access circuit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-intervention Secondary Patency at 24 Months</measure>
    <time_frame>24 months</time_frame>
    <description>Postintervention secondary patency [PSP; referred to as Access Circuit Cumulative Patency (ACCP) in the pivotal trial] was the interval following the treatment procedure until the access circuit was surgically declotted, revised, or abandoned because of inability to treat the original stenosis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Index of Patency Function (IPF) [the Average Number of Months Between Interventions] Rates of FLAIR™ and PTA at at 24 Months.</measure>
    <time_frame>24 months</time_frame>
    <description>The IPF is summarized was defined as the time from the index study procedure to complete graft abandonment divided by the number of visits for a reintervention performed on the AV access circuit in order to maintain vascular access for hemodialysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-Intervention Assisted Primary Patency at 6 Months</measure>
    <time_frame>6 month follow up</time_frame>
    <description>Postintervention assisted primary patency (PAPP) was defined as the interval after the index/study procedure until access thrombosis or a surgical intervention that excluded the treated lesion from the access circuit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-intervention Secondary Patency at 6 Months</measure>
    <time_frame>6 month follow-up</time_frame>
    <description>Postintervention secondary patency [PSP; referred to as Access Circuit Cumulative Patency (ACCP) in the pivotal trial] was the interval following the treatment procedure until the access circuit was surgically declotted, revised, or abandoned because of inability to treat the original stenosis.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">270</enrollment>
  <condition>Stenosis of Vascular Prosthetic Devices, Implants and Grafts</condition>
  <arm_group>
    <arm_group_label>FLAIR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FLAIR Endovascular Stent Graft</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PTA Only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Percutaneous Transluminal Angioplasty</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>FLAIR Endovascular Stent Graft</intervention_name>
    <description>Treatment of stenoses with primary PTA and placement of the FLAIR Endovascular Stent Graft</description>
    <arm_group_label>FLAIR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>PTA</intervention_name>
    <description>Treatment of stenoses with PTA only</description>
    <arm_group_label>PTA Only</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject must be either a male or non-pregnant female greater than or equal to 21 years
             of age

          -  Subject is willing to comply with the protocol requirements and can be contacted by
             telephone

          -  Subject has a synthetic AV access graft located in an arm that has been implanted for
             greater than or equal to 30 days and has undergone at least one successful dialysis
             session prior to the index procedure

          -  Angiographic evidence (per the institution's standard) is available to indicate that
             the subject has a stenosis greater than or equal to 50% located at the graft-vein
             anastomosis of subject's synthetic AV access graft

          -  The target lesion is estimated to be less than or equal to 7 cm in length (by
             angiography)

          -  The entire target lesion is located within 7 cm of the graft-vein anastomosis, as
             verified by angiography, such that approximately 1 cm of the FLAIR™ Endovascular Stent
             Graft will extend into non-diseased vein and approximately 1 cm but no more than 2 cm
             of the FLAIR™ Endovascular Stent Graft will extend into the non-diseased AV graft

          -  Full expansion of an appropriately sized angioplasty balloon, in the operator's
             judgment, can be achieved during primary angioplasty

          -  Graft diameter at the deployment site is between 5 mm and 8 mm as verified by
             angiography

        Exclusion Criteria:

          -  The subject has a life expectancy of &lt; 25 months.

          -  The target lesion has had a corresponding thrombosis treated less than or equal to 7
             days prior to the index procedure.

          -  A previously placed stent and/or stent graft located in the treatment area is present.
             Treatment area includes the entire target lesion and 1 cm of landing zone into both
             non-diseased AV graft and non-diseased vein.

          -  The subject has an infected AV access graft or uncontrolled systemic infection.

          -  The presence of additional lesion(s) in the access circuit less than or equal to 3 cm
             from the edges of the target lesion that was treated less than or equal to 30 days
             prior to index procedure.

          -  The presence of additional lesion(s) in the access circuit &gt; 3 cm from the edges of
             the primary lesion that are greater than or equal to 30% stenosed. Note: Subjects may
             be included if the additional lesions(s) can be successfully treated with a final
             residual stenosis of &lt; 30% prior to the index procedure.

          -  The location of the target lesion would require that the FLAIR™ Endovascular Stent
             Graft be deployed fully across the elbow joint (radiographically identified by a
             combination of the humeroulnar joint and the humeroradial joint).

          -  The location of the target lesion would require that the FLAIR™ Endovascular Stent
             Graft cross an angle (between the inflow vein and synthetic AV access graft) that is &gt;
             90 degrees.

          -  The subject has an uncontrolled blood coagulation disorder.

          -  The subject has a known allergy or sensitivity to contrast media which cannot be
             adequately pre-medicated.

          -  The subject has a known hypersensitivity to nickel-titanium.

          -  Subjects who are currently enrolled or who plan to enroll in other investigations that
             conflict with follow-up testing or confounds data in this trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ziv Haskal, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Maryland Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Access Connections</name>
      <address>
        <city>Bamberg</city>
        <state>South Carolina</state>
        <zip>29003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Haskal ZJ, Saad TF, Hoggard JG, Cooper RI, Lipkowitz GS, Gerges A, Ross JR, Pflederer TA, Mietling SW. Prospective, Randomized, Concurrently-Controlled Study of a Stent Graft versus Balloon Angioplasty for Treatment of Arteriovenous Access Graft Stenosis: 2-Year Results of the RENOVA Study. J Vasc Interv Radiol. 2016 Aug;27(8):1105-1114.e3. doi: 10.1016/j.jvir.2016.05.019. Epub 2016 Jul 4.</citation>
    <PMID>27388566</PMID>
  </results_reference>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 12, 2008</study_first_submitted>
  <study_first_submitted_qc>May 13, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 14, 2008</study_first_posted>
  <results_first_submitted>January 20, 2014</results_first_submitted>
  <results_first_submitted_qc>August 6, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 7, 2014</results_first_posted>
  <last_update_submitted>January 30, 2017</last_update_submitted>
  <last_update_submitted_qc>January 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hemodialysis</keyword>
  <keyword>Vascular Prosthesis</keyword>
  <keyword>Stenosis</keyword>
  <keyword>End-stage Renal Disease (ESRD)</keyword>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>FLAIR</title>
          <description>FLAIR Endovascular Stent Graft
FLAIR Endovascular Stent Graft: Treatment of stenoses with primary PTA and placement of the FLAIR Endovascular Stent Graft</description>
        </group>
        <group group_id="P2">
          <title>PTA Only</title>
          <description>Percutaneous Transluminal Angioplasty (PTA): Treatment of stenoses with PTA only</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="138"/>
                <participants group_id="P2" count="132"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="97"/>
                <participants group_id="P2" count="94"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="38"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="36"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Experience</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Subjects with hemodynamically significant stenosis fifty percent, clinical evidence of graft dysfunction (without thrombotic occlusion) at the synthetic AV access graft anastomosis, and who were selected from the Investigator’s general subject population were eligible for participation in this study.</population>
      <group_list>
        <group group_id="B1">
          <title>FLAIR</title>
          <description>FLAIR Endovascular Stent Graft
FLAIR Endovascular Stent Graft: Treatment of stenoses with primary PTA and placement of the FLAIR Endovascular Stent Graft</description>
        </group>
        <group group_id="B2">
          <title>PTA Only</title>
          <description>Percutaneous Transluminal Angioplasty
PTA: Treatment of stenoses with PTA only</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="138"/>
            <count group_id="B2" value="132"/>
            <count group_id="B3" value="270"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64" lower_limit="26" upper_limit="89"/>
                    <measurement group_id="B2" value="63" lower_limit="24" upper_limit="88"/>
                    <measurement group_id="B3" value="63.5" lower_limit="24" upper_limit="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                    <measurement group_id="B2" value="69"/>
                    <measurement group_id="B3" value="134"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="73"/>
                    <measurement group_id="B2" value="63"/>
                    <measurement group_id="B3" value="136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="87"/>
                    <measurement group_id="B2" value="86"/>
                    <measurement group_id="B3" value="173"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="138"/>
                    <measurement group_id="B2" value="132"/>
                    <measurement group_id="B3" value="270"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>ACPP Was Defined as the Interval Following the Index Procedure Until the Next Access Thrombosis or Reintervention.</title>
        <description>To demonstrate that the post intervention Access Circuit Primary Patency (ACPP) of FLAIR™ is superior to that of PTA at 12 months post study procedure.</description>
        <time_frame>12 months</time_frame>
        <population>All patients who were enrolled in the study were included in the analysis in the treatment group to which they were randomized, regardless of the intervention that they actually incurred (an intent-to-treat analysis).</population>
        <group_list>
          <group group_id="O1">
            <title>FLAIR</title>
            <description>FLAIR Endovascular Stent Graft
FLAIR Endovascular Stent Graft: Treatment of stenoses with primary PTA and placement of the FLAIR Endovascular Stent Graft</description>
          </group>
          <group group_id="O2">
            <title>PTA Only</title>
            <description>Percutaneous Transluminal Angioplasty
PTA: Treatment of stenoses with PTA only</description>
          </group>
        </group_list>
        <measure>
          <title>ACPP Was Defined as the Interval Following the Index Procedure Until the Next Access Thrombosis or Reintervention.</title>
          <description>To demonstrate that the post intervention Access Circuit Primary Patency (ACPP) of FLAIR™ is superior to that of PTA at 12 months post study procedure.</description>
          <population>All patients who were enrolled in the study were included in the analysis in the treatment group to which they were randomized, regardless of the intervention that they actually incurred (an intent-to-treat analysis).</population>
          <units>proportion of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="138"/>
                <count group_id="O2" value="132"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.240" lower_limit="0.165" upper_limit="0.315"/>
                    <measurement group_id="O2" value="0.110" lower_limit="0.054" upper_limit="0.167"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Index of Patency Function (IPF) [the Average Number of Months Between Interventions] of FLAIR™ is Not Inferior to That of PTA at 12 Months Post Study Procedure.</title>
        <description>The IPF is summarized was defined as the time from the index study procedure to complete graft abandonment divided by the number of visits for a reintervention performed on the arteriovenous (AV) access circuit in order to maintain vascular access for hemodialysis.</description>
        <time_frame>12 months</time_frame>
        <population>All patients who were enrolled in the study will participate in the analysis in the treatment group to which they were randomized, regardless of the intervention that they actually incurred (an intent-to-treat analysis).Blackwelder t-test testing non-inferiority of the FLAIR® group to that of PTA.</population>
        <group_list>
          <group group_id="O1">
            <title>FLAIR</title>
            <description>FLAIR Endovascular Stent Graft
FLAIR Endovascular Stent Graft: Treatment of stenoses with primary PTA and placement of the FLAIR Endovascular Stent Graft</description>
          </group>
          <group group_id="O2">
            <title>PTA Only</title>
            <description>Percutaneous Transluminal Angioplasty
PTA: Treatment of stenoses with PTA only</description>
          </group>
        </group_list>
        <measure>
          <title>The Index of Patency Function (IPF) [the Average Number of Months Between Interventions] of FLAIR™ is Not Inferior to That of PTA at 12 Months Post Study Procedure.</title>
          <description>The IPF is summarized was defined as the time from the index study procedure to complete graft abandonment divided by the number of visits for a reintervention performed on the arteriovenous (AV) access circuit in order to maintain vascular access for hemodialysis.</description>
          <population>All patients who were enrolled in the study will participate in the analysis in the treatment group to which they were randomized, regardless of the intervention that they actually incurred (an intent-to-treat analysis).Blackwelder t-test testing non-inferiority of the FLAIR® group to that of PTA.</population>
          <units>Months/intervention</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="138"/>
                <count group_id="O2" value="132"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.2" spread="4.08"/>
                    <measurement group_id="O2" value="4.4" spread="3.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Number of Participants With Device and/or Procedure Related Adverse Events at 12 Months Post Study Procedure.</title>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>FLAIR</title>
            <description>FLAIR Endovascular Stent Graft
FLAIR Endovascular Stent Graft: Treatment of stenoses with primary PTA and placement of the FLAIR Endovascular Stent Graft</description>
          </group>
          <group group_id="O2">
            <title>PTA Only</title>
            <description>Percutaneous Transluminal Angioplasty
PTA: Treatment of stenoses with PTA only</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Participants With Device and/or Procedure Related Adverse Events at 12 Months Post Study Procedure.</title>
          <units>Number of Participants with Device and/o</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
                <count group_id="O2" value="130"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="128"/>
                    <measurement group_id="O2" value="130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Assess the Number of Re-interventions to the Access Circuit Until Graft Abandonment or Through 12 Months Post-index Procedure</title>
        <description>The estimated number of re-interventions to the access circuit until graft abandonment or through 12 months post-index procedure was a secondary endpoint without hypothesis testing and is therefore summarized descriptively.</description>
        <time_frame>Patient Follow-Up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>FLAIR</title>
            <description>FLAIR Endovascular Stent Graft
FLAIR Endovascular Stent Graft: Treatment of stenoses with primary PTA and placement of the FLAIR Endovascular Stent Graft</description>
          </group>
          <group group_id="O2">
            <title>PTA Only</title>
            <description>Percutaneous Transluminal Angioplasty
PTA: Treatment of stenoses with PTA only</description>
          </group>
        </group_list>
        <measure>
          <title>To Assess the Number of Re-interventions to the Access Circuit Until Graft Abandonment or Through 12 Months Post-index Procedure</title>
          <description>The estimated number of re-interventions to the access circuit until graft abandonment or through 12 months post-index procedure was a secondary endpoint without hypothesis testing and is therefore summarized descriptively.</description>
          <units>reinterventions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="138"/>
                <count group_id="O2" value="132"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" spread="2.18"/>
                    <measurement group_id="O2" value="2.4" spread="2.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-Intervention Assisted Primary Patency at 12 Months</title>
        <description>Postintervention assisted primary patency (PAPP) was defined as the interval after the index/study procedure until access thrombosis or a surgical intervention that excluded the treated lesion from the access circuit.</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>FLAIR</title>
            <description>FLAIR Endovascular Stent Graft
FLAIR Endovascular Stent Graft: Treatment of stenoses with primary PTA and placement of the FLAIR Endovascular Stent Graft</description>
          </group>
          <group group_id="O2">
            <title>PTA Only</title>
            <description>Percutaneous Transluminal Angioplasty
PTA: Treatment of stenoses with PTA only</description>
          </group>
        </group_list>
        <measure>
          <title>Post-Intervention Assisted Primary Patency at 12 Months</title>
          <description>Postintervention assisted primary patency (PAPP) was defined as the interval after the index/study procedure until access thrombosis or a surgical intervention that excluded the treated lesion from the access circuit.</description>
          <units>proportion of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="138"/>
                <count group_id="O2" value="132"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.497" lower_limit="0.410" upper_limit="0.584"/>
                    <measurement group_id="O2" value="0.563" lower_limit="0.474" upper_limit="0.653"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-intervention Secondary Patency (PSP) at 12 Months</title>
        <description>Postintervention secondary patency [PSP; referred to as Access Circuit Cumulative Patency (ACCP) in the pivotal trial] was the interval following the treatment procedure until the access circuit was surgically declotted, revised, or abandoned because of inability to treat the original stenosis.</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>FLAIR</title>
            <description>FLAIR Endovascular Stent Graft
FLAIR Endovascular Stent Graft: Treatment of stenoses with primary PTA and placement of the FLAIR Endovascular Stent Graft</description>
          </group>
          <group group_id="O2">
            <title>PTA Only</title>
            <description>Percutaneous Transluminal Angioplasty
PTA: Treatment of stenoses with PTA only</description>
          </group>
        </group_list>
        <measure>
          <title>Post-intervention Secondary Patency (PSP) at 12 Months</title>
          <description>Postintervention secondary patency [PSP; referred to as Access Circuit Cumulative Patency (ACCP) in the pivotal trial] was the interval following the treatment procedure until the access circuit was surgically declotted, revised, or abandoned because of inability to treat the original stenosis.</description>
          <units>proportion of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="138"/>
                <count group_id="O2" value="132"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.653" lower_limit="0.569" upper_limit="0.736"/>
                    <measurement group_id="O2" value="0.710" lower_limit="0.629" upper_limit="0.792"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Procedural Success</title>
        <description>Procedural success was a secondary endpoint without hypothesis testing and is therefore summarized descriptively. Procedural success is defined as anatomic success and at least one indicator of hemodynamic or clinical success.</description>
        <time_frame>Patient Follow-Up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>FLAIR</title>
            <description>FLAIR Endovascular Stent Graft
FLAIR Endovascular Stent Graft: Treatment of stenoses with primary PTA and placement of the FLAIR Endovascular Stent Graft</description>
          </group>
          <group group_id="O2">
            <title>PTA Only</title>
            <description>Percutaneous Transluminal Angioplasty
PTA: Treatment of stenoses with PTA only</description>
          </group>
        </group_list>
        <measure>
          <title>Procedural Success</title>
          <description>Procedural success was a secondary endpoint without hypothesis testing and is therefore summarized descriptively. Procedural success is defined as anatomic success and at least one indicator of hemodynamic or clinical success.</description>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="138"/>
                <count group_id="O2" value="132"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.2"/>
                    <measurement group_id="O2" value="75.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Analysis of Proportion of Serious Adverse Events Classified as Device and/or Procedure-Related Through 30 Days Post-Procedure</title>
        <description>The incidence of device-related and procedure-related serious adverse events (SAEs) from the index procedure through 30 days post procedure is summarized. The purpose of this analysis was to assess the effectiveness of the Bard Peripheral Vascular (BPV) clinician training program.</description>
        <time_frame>Patient Follow-Up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>FLAIR</title>
            <description>FLAIR Endovascular Stent Graft
FLAIR Endovascular Stent Graft: Treatment of stenoses with primary PTA and placement of the FLAIR Endovascular Stent Graft</description>
          </group>
          <group group_id="O2">
            <title>PTA Only</title>
            <description>Percutaneous Transluminal Angioplasty
PTA: Treatment of stenoses with PTA only</description>
          </group>
        </group_list>
        <measure>
          <title>Analysis of Proportion of Serious Adverse Events Classified as Device and/or Procedure-Related Through 30 Days Post-Procedure</title>
          <description>The incidence of device-related and procedure-related serious adverse events (SAEs) from the index procedure through 30 days post procedure is summarized. The purpose of this analysis was to assess the effectiveness of the Bard Peripheral Vascular (BPV) clinician training program.</description>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="138"/>
                <count group_id="O2" value="132"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Demonstrate Non-inferiority of FLAIR Safety in Terms of Serious Adverse Events at 12 Months</title>
        <description>Serious Adverse Events at 12 months are reported for all 270 subjects.</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>FLAIR</title>
            <description>FLAIR Endovascular Stent Graft
FLAIR Endovascular Stent Graft: Treatment of stenoses with primary PTA and placement of the FLAIR Endovascular Stent Graft</description>
          </group>
          <group group_id="O2">
            <title>PTA Only</title>
            <description>Percutaneous Transluminal Angioplasty
PTA: Treatment of stenoses with PTA only</description>
          </group>
        </group_list>
        <measure>
          <title>Demonstrate Non-inferiority of FLAIR Safety in Terms of Serious Adverse Events at 12 Months</title>
          <description>Serious Adverse Events at 12 months are reported for all 270 subjects.</description>
          <units>percentage of participants with serious</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="138"/>
                <count group_id="O2" value="132"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.9"/>
                    <measurement group_id="O2" value="65.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.449</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Access Circuit Primary Patency (ACCP) at 24 Months Procedure Until the Next Access Thrombosis or Reintervention.</title>
        <description>Access Circuit Primary Patency (ACPP) was defined as the interval following the index procedure until the next access thrombosis or reintervention at 24 months.</description>
        <time_frame>24 months</time_frame>
        <population>All patients who were enrolled in the study were included in the analysis in the treatment group to which they were randomized, regardless of the intervention that they actually incurred (an intent-to-treat analysis).</population>
        <group_list>
          <group group_id="O1">
            <title>FLAIR</title>
            <description>FLAIR Endovascular Stent Graft
FLAIR Endovascular Stent Graft: Treatment of stenoses with primary PTA and placement of the FLAIR Endovascular Stent Graft</description>
          </group>
          <group group_id="O2">
            <title>PTA Only</title>
            <description>Percutaneous Transluminal Angioplasty
PTA: Treatment of stenoses with PTA only</description>
          </group>
        </group_list>
        <measure>
          <title>Access Circuit Primary Patency (ACCP) at 24 Months Procedure Until the Next Access Thrombosis or Reintervention.</title>
          <description>Access Circuit Primary Patency (ACPP) was defined as the interval following the index procedure until the next access thrombosis or reintervention at 24 months.</description>
          <population>All patients who were enrolled in the study were included in the analysis in the treatment group to which they were randomized, regardless of the intervention that they actually incurred (an intent-to-treat analysis).</population>
          <units>proportion of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="138"/>
                <count group_id="O2" value="132"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.095" lower_limit="0.029" upper_limit="0.162"/>
                    <measurement group_id="O2" value="0.055" lower_limit="0.013" upper_limit="0.097"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Estimate Safety at 24 Months.</title>
        <description>To estimate the percentage of participants without safety issues through 24 months.</description>
        <time_frame>24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>FLAIR</title>
            <description>FLAIR Endovascular Stent Graft
FLAIR Endovascular Stent Graft: Treatment of stenoses with primary PTA and placement of the FLAIR Endovascular Stent Graft</description>
          </group>
          <group group_id="O2">
            <title>PTA Only</title>
            <description>Percutaneous Transluminal Angioplasty
PTA: Treatment of stenoses with PTA only</description>
          </group>
        </group_list>
        <measure>
          <title>To Estimate Safety at 24 Months.</title>
          <description>To estimate the percentage of participants without safety issues through 24 months.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="138"/>
                <count group_id="O2" value="132"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.9"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-Intervention Assisted Primary Patency at 24 Months</title>
        <description>Postintervention assisted primary patency (PAPP) was defined as the interval after the index/study procedure until access thrombosis or a surgical intervention that excluded the treated lesion from the access circuit.</description>
        <time_frame>24 month follow up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>FLAIR</title>
            <description>FLAIR Endovascular Stent Graft
FLAIR Endovascular Stent Graft: Treatment of stenoses with primary PTA and placement of the FLAIR Endovascular Stent Graft</description>
          </group>
          <group group_id="O2">
            <title>PTA Only</title>
            <description>Percutaneous Transluminal Angioplasty
PTA: Treatment of stenoses with PTA only</description>
          </group>
        </group_list>
        <measure>
          <title>Post-Intervention Assisted Primary Patency at 24 Months</title>
          <description>Postintervention assisted primary patency (PAPP) was defined as the interval after the index/study procedure until access thrombosis or a surgical intervention that excluded the treated lesion from the access circuit.</description>
          <units>proportion of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="138"/>
                <count group_id="O2" value="132"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.384" lower_limit="0.282" upper_limit="0.486"/>
                    <measurement group_id="O2" value="0.406" lower_limit="0.312" upper_limit="0.500"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-intervention Secondary Patency at 24 Months</title>
        <description>Postintervention secondary patency [PSP; referred to as Access Circuit Cumulative Patency (ACCP) in the pivotal trial] was the interval following the treatment procedure until the access circuit was surgically declotted, revised, or abandoned because of inability to treat the original stenosis.</description>
        <time_frame>24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>FLAIR</title>
            <description>FLAIR Endovascular Stent Graft
FLAIR Endovascular Stent Graft: Treatment of stenoses with primary PTA and placement of the FLAIR Endovascular Stent Graft</description>
          </group>
          <group group_id="O2">
            <title>PTA Only</title>
            <description>Percutaneous Transluminal Angioplasty
PTA: Treatment of stenoses with PTA only</description>
          </group>
        </group_list>
        <measure>
          <title>Post-intervention Secondary Patency at 24 Months</title>
          <description>Postintervention secondary patency [PSP; referred to as Access Circuit Cumulative Patency (ACCP) in the pivotal trial] was the interval following the treatment procedure until the access circuit was surgically declotted, revised, or abandoned because of inability to treat the original stenosis.</description>
          <units>proportion of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="138"/>
                <count group_id="O2" value="132"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.518" lower_limit="0.410" upper_limit="0.626"/>
                    <measurement group_id="O2" value="0.574" lower_limit="0.481" upper_limit="0.668"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Index of Patency Function (IPF) [the Average Number of Months Between Interventions] Rates of FLAIR™ and PTA at at 24 Months.</title>
        <description>The IPF is summarized was defined as the time from the index study procedure to complete graft abandonment divided by the number of visits for a reintervention performed on the AV access circuit in order to maintain vascular access for hemodialysis.</description>
        <time_frame>24 months</time_frame>
        <population>All patients who were enrolled in the study will participate in the analysis in the treatment group to which they were randomized, regardless of the intervention that they actually incurred (an intent-to-treat analysis).Blackwelder t-test testing non-inferiority of the FLAIR® group to that of PTA.</population>
        <group_list>
          <group group_id="O1">
            <title>FLAIR</title>
            <description>FLAIR Endovascular Stent Graft
FLAIR Endovascular Stent Graft: Treatment of stenoses with primary PTA and placement of the FLAIR Endovascular Stent Graft</description>
          </group>
          <group group_id="O2">
            <title>PTA Only</title>
            <description>Percutaneous Transluminal Angioplasty
PTA: Treatment of stenoses with PTA only</description>
          </group>
        </group_list>
        <measure>
          <title>Index of Patency Function (IPF) [the Average Number of Months Between Interventions] Rates of FLAIR™ and PTA at at 24 Months.</title>
          <description>The IPF is summarized was defined as the time from the index study procedure to complete graft abandonment divided by the number of visits for a reintervention performed on the AV access circuit in order to maintain vascular access for hemodialysis.</description>
          <population>All patients who were enrolled in the study will participate in the analysis in the treatment group to which they were randomized, regardless of the intervention that they actually incurred (an intent-to-treat analysis).Blackwelder t-test testing non-inferiority of the FLAIR® group to that of PTA.</population>
          <units>Months/intervention</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="138"/>
                <count group_id="O2" value="132"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1" spread="7.04"/>
                    <measurement group_id="O2" value="5.3" spread="5.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-Intervention Assisted Primary Patency at 6 Months</title>
        <description>Postintervention assisted primary patency (PAPP) was defined as the interval after the index/study procedure until access thrombosis or a surgical intervention that excluded the treated lesion from the access circuit.</description>
        <time_frame>6 month follow up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>FLAIR</title>
            <description>FLAIR Endovascular Stent Graft
FLAIR Endovascular Stent Graft: Treatment of stenoses with primary PTA and placement of the FLAIR Endovascular Stent Graft</description>
          </group>
          <group group_id="O2">
            <title>PTA Only</title>
            <description>Percutaneous Transluminal Angioplasty
PTA: Treatment of stenoses with PTA only</description>
          </group>
        </group_list>
        <measure>
          <title>Post-Intervention Assisted Primary Patency at 6 Months</title>
          <description>Postintervention assisted primary patency (PAPP) was defined as the interval after the index/study procedure until access thrombosis or a surgical intervention that excluded the treated lesion from the access circuit.</description>
          <units>proportion of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="138"/>
                <count group_id="O2" value="132"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.596" lower_limit="0.512" upper_limit="0.681"/>
                    <measurement group_id="O2" value="0.656" lower_limit="0.573" upper_limit="0.740"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-intervention Secondary Patency at 6 Months</title>
        <description>Postintervention secondary patency [PSP; referred to as Access Circuit Cumulative Patency (ACCP) in the pivotal trial] was the interval following the treatment procedure until the access circuit was surgically declotted, revised, or abandoned because of inability to treat the original stenosis.</description>
        <time_frame>6 month follow-up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>FLAIR</title>
            <description>FLAIR Endovascular Stent Graft
FLAIR Endovascular Stent Graft: Treatment of stenoses with primary PTA and placement of the FLAIR Endovascular Stent Graft</description>
          </group>
          <group group_id="O2">
            <title>PTA Only</title>
            <description>Percutaneous Transluminal Angioplasty
PTA: Treatment of stenoses with PTA only</description>
          </group>
        </group_list>
        <measure>
          <title>Post-intervention Secondary Patency at 6 Months</title>
          <description>Postintervention secondary patency [PSP; referred to as Access Circuit Cumulative Patency (ACCP) in the pivotal trial] was the interval following the treatment procedure until the access circuit was surgically declotted, revised, or abandoned because of inability to treat the original stenosis.</description>
          <units>proportion of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="138"/>
                <count group_id="O2" value="132"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.748" lower_limit="0.673" upper_limit="0.822"/>
                    <measurement group_id="O2" value="0.793" lower_limit="0.722" upper_limit="0.864"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Treatment Area Primary Patency (TAPP) at 12 Months.</title>
        <description>TAPP is defined as patency (open to blood flow) after the study index procedure until reintervention in the treatment area (within 5mm proximal or 5mm distal to the study device or index balloon angioplasty treated area), or thrombotic occlusion that involved the treatment area.</description>
        <time_frame>12 months follow up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>FLAIR</title>
            <description>FLAIR Endovascular Stent Graft
FLAIR Endovascular Stent Graft: Treatment of stenoses with primary PTA and placement of the FLAIR Endovascular Stent Graft</description>
          </group>
          <group group_id="O2">
            <title>PTA Only</title>
            <description>Percutaneous Transluminal Angioplasty
PTA: Treatment of stenoses with PTA only</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment Area Primary Patency (TAPP) at 12 Months.</title>
          <description>TAPP is defined as patency (open to blood flow) after the study index procedure until reintervention in the treatment area (within 5mm proximal or 5mm distal to the study device or index balloon angioplasty treated area), or thrombotic occlusion that involved the treatment area.</description>
          <units>proportion of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="138"/>
                <count group_id="O2" value="132"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.476" lower_limit="0.389" upper_limit="0.564"/>
                    <measurement group_id="O2" value="0.248" lower_limit="0.170" upper_limit="0.325"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Treatment Area Primary Patency (TAPP) at 24 Months.</title>
        <description>TAPP is defined as patency (open to blood flow) after the study index procedure until reintervention in the treatment area (within 5mm proximal or 5mm distal to the study device or index balloon angioplasty treated area), or thrombotic occlusion that involved the treatment area.</description>
        <time_frame>24 months follow-up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>FLAIR</title>
            <description>FLAIR Endovascular Stent Graft
FLAIR Endovascular Stent Graft: Treatment of stenoses with primary PTA and placement of the FLAIR Endovascular Stent Graft</description>
          </group>
          <group group_id="O2">
            <title>PTA Only</title>
            <description>Percutaneous Transluminal Angioplasty
PTA: Treatment of stenoses with PTA only</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment Area Primary Patency (TAPP) at 24 Months.</title>
          <description>TAPP is defined as patency (open to blood flow) after the study index procedure until reintervention in the treatment area (within 5mm proximal or 5mm distal to the study device or index balloon angioplasty treated area), or thrombotic occlusion that involved the treatment area.</description>
          <units>proportion of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="138"/>
                <count group_id="O2" value="132"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.269" lower_limit="0.177" upper_limit="0.360"/>
                    <measurement group_id="O2" value="0.135" lower_limit="0.068" upper_limit="0.202"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From Index Procedure through 24 months of follow-up.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>FLAIR</title>
          <description>FLAIR Endovascular Stent Graft
FLAIR Endovascular Stent Graft: Treatment of stenoses with primary PTA and placement of the FLAIR Endovascular Stent Graft</description>
        </group>
        <group group_id="E2">
          <title>PTA Only</title>
          <description>Percutaneous Transluminal Angioplasty
PTA: Treatment of stenoses with PTA only</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="84" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="87" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>hemotoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="138"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Hemorrhage</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="138"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="138"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Congestive heart failure</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="138"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="32" subjects_affected="32" subjects_at_risk="138"/>
                <counts group_id="E2" events="33" subjects_affected="33" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="138"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Pseudoaneurysm</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="138"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Significant arm or hand edema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Stenosis requiring intervention</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="138"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Thrombotic occlusion</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="138"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" events="69" subjects_affected="69" subjects_at_risk="138"/>
                <counts group_id="E2" events="69" subjects_affected="69" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="128" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="127" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="138"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular Accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Congestive heart failure</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="138"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Hematoma</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="138"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Hemorrhage</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="138"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Hemorrhage</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="138"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Pseudoaneurysm</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="138"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Significant arm or hand edema</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="138"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Steal syndrome</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="138"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Stenosis requiring intervention</sub_title>
                <counts group_id="E1" events="82" subjects_affected="82" subjects_at_risk="138"/>
                <counts group_id="E2" events="103" subjects_affected="103" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Thrombotic occlusion</sub_title>
                <counts group_id="E1" events="47" subjects_affected="47" subjects_at_risk="138"/>
                <counts group_id="E2" events="45" subjects_affected="45" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Vessel rupture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="138"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="138"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>John Van Vleet</name_or_title>
      <organization>Bard Peripheral Vascular</organization>
      <phone>1-800-321-4254</phone>
      <email>John.VanVleet@CRBard.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

